rawfin.tv
Apogee Therapeutics CEO Sells 20,000 Shares Via 10b5-1 Plan
MarketsstocksAI Generated

Apogee Therapeutics CEO Sells 20,000 Shares Via 10b5-1 Plan

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Apogee Therapeutics (APGE) CEO Michael Thomas Henderson sold 20,000 shares of common stock on May 13, 2026, as part of a pre-arranged 10b5-1 trading plan. Such sales are scheduled in advance and do not necessarily reflect a change in the executive's outlook.

APGEInsider Trading10b5-1 PlanBiotechnology

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks